A process for the preparation of sterile ensifentrine
The process of gamma or e-beam irradiation with controlled packaging and cooling effectively prepares sterile Ensifentrine, addressing degradation issues and environmental concerns in existing methods, ensuring effective and efficient sterilization.
Patent Information
- Application Number
- PCT/IN2026/050794
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for sterilizing Ensifentrine, a pharmaceutical compound used to treat Chronic Obstructive Pulmonary Disease (COPD), cause degradation and are not environmentally friendly.
A process utilizing gamma irradiation or e-beam irradiation, combined with specific packaging and cooling methods, to prepare sterile Ensifentrine without significant degradation, suitable for large-scale operations.
Ensures sterility while maintaining the integrity of Ensifentrine, avoiding environmental impact and reducing degradation, with faster and more cost-effective results compared to traditional sterilization methods.
Smart Images

Figure IN2026050794_12112026_PF_FP_ABST
Abstract
Description
[0001] A PROCESS FOR THE PREPARATION OF STERILE ENSIFENTRINE RELATED PATENT APPLICATION
[0002] This application claims the priority to and benefit of Indian Provisional Patent Application No. 202541045149, which was filed on May 09, 2025; the disclosures of which are incorporated herein by reference.
[0003] FIELD OF THE INVENTION
[0004] The present invention relates to a process for the preparation of sterile Ensifentrine of Formula-I,
[0005]
[0006] BACKGROUND OF THE INVENTION
[0007] Ensifentrine is chemically known as N-(2-{(2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-6,7-dihydro-2H-pyrimido[6,l-a]isoquinolin3(4H)-yl}ethyl)urea. The molecular formula is C26H31N5O4 and the molecular weight is 477.565 grams per mole. It has the following structure of formula-I.
[0008]
[0009] Ensifentrine (RPL554) is a first-in-class, inhaled, dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. Ensifentrine is used to treat Chronic obstructive pulmonary disease (COPD).US 6,794,391 B2 (Vernalis / Verona Pharma) discloses Ensifentrine or salt thereof. This patent discloses a process for the preparation of Ensifentrine of formula-I, which involves chlorination of 9,10-dimethoxy-6,7-dihydro-2H-pyrimido[6,l-a]isoquinoline-2,4(3H)-dione of formula-II with POCI3 to obtain a compound of formula- III, then coupled with a compound of formula- IV in the presence of IPA to obtain a compound of formula-V, which is purified by column chromatography. Protection of compound of formula-V with a compound of formula- VI in the presence of K2CO3, Nal, 2-butanone to obtain a compound of formula- VII, which is purified by column chromatography. Deprotection of compound of formula- VII with hydrazine hydrate, in the presence of chloroform and EtOH to obtain a compound of formula- VIII, followed by reacting with NaOCN in the presence of H2O and HC1 to obtain a compound of Formula-I, which is purified by column chromatography. The process is schematically shown below in Scheme-I:
[0010] IPA
[0011] Purified by column chromatography Formula-] V Step-II Formula-Ill
[0012] K2CO3, Nal, 2-Butanone Column chromatography Step-Ill
[0013] Hydrazine hydrate, Step-IV Chloroform, EtOH
[0014]
[0015] Scheme-IUS 9,956,171 B2 (Verona Pharma) discloses a liquid pharmaceutical composition suitable for administration by inhalation comprising a diluent and a suspension of particles of 9, 10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,l-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof, wherein the particles of RPL554 have a particle size distribution with a Dv50 (median particle size by volume) value of from about 0.2 pm to about 5 pm.
[0016] US 12,168,011 B2 (Verona Pharma) discloses a method for producing a sterile liquid pharmaceutical composition comprising sterile Ensifentrine particles suitable for administration by inhalation, the method comprising:
[0017] a) heating Ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain the sterile Ensifentrine particles, wherein the heating produces less than a 0.5% w / w increase in total impurities; and
[0018] b) combining the sterile Ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation.
[0019] Certain pharmaceutical products must meet stringent sterility standards before they can be administered to patients. In view of the importance of sterility for pharmaceutical products, a large number of different processes, protocols, and techniques have been developed for sterilization of pharmaceutical products. These include steam sterilization, dry heat sterilization, ionising radiation sterilization (including x-ray and gamma-ray sterilization), gas sterilization, sterile filtration and aseptic processing. The selection of a sterilization protocol for a new pharmaceutical product is a complex process which relies on the evaluation of the various available methods and their suitability for the specific product.
[0020] Hence, there is a need to develop a process for producing a sterilised Ensifentrine suspension.The present inventors have found that, of all the available sterilisation techniques, gamma irradiation, or e-beam irradiation of particles of Ensifentrine is particularly well-suited to formulation of Ensifentrine as a suspension. Other techniques such as dry heat sterilization or terminal sterilisation were found to cause degradation of the formulations.
[0021] Therefore, it would be desirable and of paramount importance to have an environmentally friendly process for the preparation of sterile Ensifentrine of Formula-I, by employing without any impact on environment and control all degradation impurities by providing detailed experimental procedure.
[0022] OBJECTS OF THE INVENTION
[0023] The main object of the present invention is to provide a process for the preparation of sterile Ensifentrine using gamma irradiation, or e-beam irradiation, which is industrially viable and suitable for large-scale operations.
[0024] SUMMARY OF THE INVENTION
[0025] The present invention provides an improved process for the preparation of sterile Ensifentrine. Preferred methods of sterilization include gamma irradiation and e-beam irradiation.
[0026] In one aspect, the present invention provides a process for the preparation of sterile Ensifentrine of Formula-I,
[0027]
[0028] which comprises:i. placing the Ensifentrine non- sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature;
[0029] ii. placing the LDPE bag into a secondary LDPE bag and remove the air and seal the bag with heat seal or twist tie at room temperature;
[0030] iii. placing the above bag into triple-laminated aluminium bag and close the bag with heat seal or twist tie and covering the bag with LDPE cover without air at room temperature;
[0031] iv. placing the triple-laminated aluminium bag into the HDPE drum at room temperature;
[0032] v. loading the dry ice into HDPE drum and hold the sample for about 1 hour to about 30 hours under dry ice;
[0033] vi. placing the HDPE drum into a thermocol box along with dry ice;
[0034] vii. placing the thermocol box into aluminium tote box; and
[0035] viii. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy.
[0036] OR
[0037] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
[0038] In another aspect, the present invention provides a process for the preparation of sterile Ensifentrine of Formula-I,
[0039] MeO
[0040]
[0041] Formula-I
[0042] which comprises:i. placing the Ensifentrine non- sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature;
[0043] ii. placing the LDPE bag into a secondary LDPE bag and remove the air and seal the bag with heat seal or twist tie at room temperature;
[0044] iii. covering the secondary LDPE bag with LDPE cover without air at room temperature;
[0045] iv. placing the bag into the HDPE drum at room temperature;
[0046] v. loading the dry ice into HDPE drum and hold the sample for about 1 hour to about 30 hours under dry ice;
[0047] vi. placing the HDPE drum into a thermocol box along with dry ice;
[0048] vii. placing the thermocol box into aluminium tote box; and
[0049] viii. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy.
[0050] OR
[0051] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
[0052] In another aspect, the present invention provides a process for the preparation of sterile Ensifentrine of Formula-I,
[0053] MeO
[0054]
[0055] Formula-I
[0056] which comprises:
[0057] i. placing the Ensifentrine non- sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature;
[0058] ii. placing the LDPE bag into aluminium canister at room temperature;iii. closing the aluminium canister with chlorobutyl plug and tear off aluminium caps at room temperature;
[0059] iv. sealing the aluminium canister using a crimper at room temperature; v. covering the aluminium canister with LDPE cover, remove the air, seal or twist and tie;
[0060] vi. placing the canister and load dry ice into the thermocol box and seal the box with cello tape and hold the box under dry ice for about 1 hour to about 30 hours;
[0061] vii. placing the thermocol box into an aluminium tote box along with dry ice;
[0062] and
[0063] viii. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy.
[0064] OR
[0065] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
[0066] In another aspect, the present invention provides a process for the preparation of sterile Ensifentrine of Formula-I,
[0067]
[0068] which comprises:
[0069] i. placing the Ensifentrine non-sterile sample in aluminium canister at room temperature;
[0070] ii. closing the aluminium canister with chlorobutyl plug and tear off aluminium caps at room temperature;
[0071] iii. sealing the aluminium canister using a crimper at room temperature;iv. covering the aluminium canister with an LDPE cover, remove the air and seal or twist and tie;
[0072] v. placing the canister and load dry ice into the thermocol box and seal the box with cello tape and hold the box under dry ice for about 1 hour to about 30 hours;
[0073] vi. placing the thermocol box into an aluminium tote box along with dry ice;
[0074] and
[0075] vii. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 hour to about 24 kGy.
[0076] OR
[0077] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
[0078] In another aspect, the present invention provides a process for the preparation of sterile Ensifentrine of Formula-I,
[0079] O
[0080] N.
[0081] H
[0082] N
[0083]
[0084] Formula-I
[0085] which comprises:
[0086] i. placing the Ensifentrine non-sterile sample in triple laminated aluminium bag at room temperature;
[0087] ii. closing the bag using heat seal or twist and tie at room temperature; iii. placing the bag into HDPE container;
[0088] iv. placing the HDPE container into thermocol box and loading the dry ice into thermocol box and seal the box with cello tape and hold the box for about 1 hour to about 30 hours under dry ice.
[0089] v. placing the thermocol box into the aluminium tote box along with dry ice;
[0090] andvi. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy.
[0091] OR
[0092] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
[0093] DETAILED DESCRIPTION OF THE INVENTION
[0094] The present invention provides an improved process for the preparation of sterile Ensifentrine. Preferred methods of sterilization include gamma irradiation, and e-beam irradiation.
[0095] The present invention includes the use of certain packaging materials to store active substance or pharmaceutical formulations.
[0096] Unless otherwise stated, the following terms used in the specification have the meanings given below:
[0097] The term “sterile” refers to a composition which is essentially free of viable microbes. As such, a sterile composition is typically a composition which is substantially free of viable bacteria or fungi. The term “sterile” is well known in the art. As used herein, a material will be considered "sterile" when the probability of a surviving microorganism is less than one in a million, which is expressed as a sterility assurance level ("SAL") of 10’6or better. A SAL of 10’6means that statistically, less than one in every million samples of material carries a viable organism. For instance, an SAL of 10’6means that the probability that a final product is non-sterile is 1 / 106. SAL can be determined using methods known in the art, for example, U.S. Pharmacopeia (USP<71>) or European Pharmacopoeia (Ph.Eur<2.6.1>).
[0098] "Gamma irradiation sterilization," as used herein, refers to sterilization methods that uses gamma radiation. Gamma rays typically have frequencies above 1019Hz and wavelengths less than 10 metre (m). Exposure to gamma radiation can result in alteration of molecular bonds of some compositions and it would have beenpresumed by those skilled in the art that exposure to gamma irradiation sterilization would have resulted in the alteration of the labile moieties.
[0099] "Electron-beam sterilization," also referred to as "e-beam sterilization," refers to a sterilization method that uses a concentrated, highly charged stream of electrons. Exposure to e-beam irradiation can result in alteration of molecular bonds of some compositions and it would have been presumed by those skilled in the art that exposure to e-beam irradiation would have resulted in the alteration of the labile moieties.
[0100] As used herein, "absorbed dose" is the measure of the energy deposited into the material being sterilized by gamma or e-beam irradiation. The energy is measured in units of kiloGrays (kGy), one kGy being equal to 1,000 Joules per kilogram.
[0101] The invention includes use of packaging materials such as containers and lids of high-density polyethylene (HDPE), low-density polyethylene (LDPE) and / or polypropylene and / or glass, and blisters or strips composed of aluminum or high-density polypropylene, polyvinyl chloride, polyvinyl dichloride and so on. Its colours viz., the "Black" or any other dark colour inside and the "White" or any other light colour outside for this particular purpose of opaqueness.
[0102] The word ‘Canister’ means a round or cylindrical aluminium container.
[0103] Accordingly, the present invention provides a process for the preparation of sterile Ensifentrine of Formula I,
[0104]
[0105] The main embodiment of the present invention provides a process for the preparation of sterile Ensifentrine as shown below:
[0106] In step-i), placing the Ensifentrine non-sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature; this process is optionally carried out under a nitrogen atmosphere; In step-ii), placing the LDPE bag into a secondary LDPE bag and remove the air and seal the bag with heat seal or twist tie at room temperature; this process is optionally carried out under a nitrogen atmosphere;
[0107] In step-iii), placing the above bag into triple-laminated aluminium bag and close the bag with heat seal or twist tie and covering the bag with LDPE cover without air at room temperature; this process is optionally carried out under a nitrogen atmosphere;
[0108] In step-iv) placing the triple-laminated aluminium bag into the HDPE drum at room temperature;
[0109] In step-v), loading the dry ice into HDPE drum and hold the sample for sufficient period of time; preferably, about 1 hour to about 30 hours under dry ice; most preferably, about 4 hours to about 8 hours;
[0110] In step-vi), placing the HDPE drum into a thermocol box along with dry ice;
[0111] In step-vii), placing the thermocol box into aluminium tote box; and
[0112] In step-viii), exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy; preferably, about 15 kGy to about 24 kGy.
[0113] OR
[0114] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 to about 50 kGy; preferably, about 15 kGy to about 25 kGy.
[0115] In another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine as shown below:In step-i), placing the Ensifentrine non-sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature; this process is optionally carried out under a nitrogen atmosphere; In step-ii), placing the LDPE bag into a secondary LDPE bag and remove the air and seal the bag with heat seal or twist tie at room temperature; this process is optionally carried out under a nitrogen atmosphere;
[0116] In step-iii), covering the secondary LDPE bag with LDPE cover without air at room temperature; this process is optionally carried out under a nitrogen atmosphere; In step-iv), placing the bag into the HDPE drum at room temperature;
[0117] In step-v), loading the dry ice into HDPE drum and hold the sample for sufficient period of time; preferably, about 1 hour to about 30 hours under dry ice; most preferably, about 4 hours to about 8 hours;
[0118] In step-vi), placing the HDPE drum into a thermocol box along with dry ice;
[0119] In step-vii), placing the thermocol box into aluminium tote box;
[0120] In step-viii), exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy; preferably, about 15 kGy to about 24 kGy.
[0121] OR
[0122] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy; preferably, about 15 kGy to about 25 kGy.
[0123] In another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine as shown below:
[0124] In step-i), placing the Ensifentrine non-sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature; this process is optionally carried out under a nitrogen atmosphere; In step-ii), placing the LDPE bag into aluminium canister at room temperature; this process is optionally carried out under a nitrogen atmosphere;In step-iii), closing the aluminium canister with chlorobutyl plug and tear off aluminium caps at room temperature; this process is optionally carried out under a nitrogen atmosphere;
[0125] In step-iv), sealing the aluminium canister using a crimper at room temperature; In step-v), covering the aluminium canister with LDPE cover, remove the air, seal or twist and tie;
[0126] In step-vi), placing the canister and load dry ice into the thermocol box and seal the box with cello tape and hold the box under dry ice for sufficient period of time; preferably, about 1 hour to about 30 hours; most preferably, about 4 hours to about 8 hours;
[0127] In step-vii), placing the thermocol box into an aluminium tote box along with dry ice;
[0128] In step-viii), exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy; preferably, about 15 kGy to about 24 kGy.
[0129] OR
[0130] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy; preferably, about 15 kGy to about 25 kGy.
[0131] In another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine as shown below:
[0132] In step-i), placing the Ensifentrine non-sterile sample in aluminium canister at room temperature; this process is optionally carried out under a nitrogen atmosphere; In step-ii), closing the aluminium canister with chlorobutyl plug and tear off aluminium caps at room temperature; this process is optionally carried out under a nitrogen atmosphere;
[0133] In step-iii), sealing the aluminium canister using a crimper at room temperature; this process is optionally carried out under a nitrogen atmosphere;In step-iv), covering the aluminium canister with LDPE cover, remove the air and seal or twist and tie; this process is optionally carried out under a nitrogen atmosphere;
[0134] In step-v), placing the canister and load dry ice into the thermocol box and seal the box with cello tape and hold the box under dry ice for sufficient period of time; preferably, about 1 hour to about 30 hours; most preferably, about 4 hours to about 8 hours;
[0135] In step-vi), placing the thermocol box into an aluminium tote box along with dry ice;
[0136] In step-vii), exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy; preferably, about 15 kGy to about 24 kGy.
[0137] OR
[0138] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy; preferably, about 15 kGy to about 25 kGy.
[0139] In another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine as shown below:
[0140] In step-i), placing the Ensifentrine non-sterile sample in triple laminated aluminium bag at room temperature; this process is optionally carried out under a nitrogen atmosphere;
[0141] In step-ii), closing the bag using heat seal or twist and tie at room temperature; this process is optionally carried out under a nitrogen atmosphere;
[0142] In step-iii), placing the bag into HDPE container; this process is optionally carried out under a nitrogen atmosphere;
[0143] In step-iv), placing the HDPE container into thermocol box and loading the dry ice into thermocol box and seal the box with cello tape and hold the box for sufficient period of time; preferably, about 1 hour to about 30 hours under dry ice.
[0144] In step-v), placing the thermocol box into the aluminium tote box along with dry ice;In step-vi), exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy; preferably, about 15 kGy to about 24 kGy.
[0145] OR
[0146] exposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy; preferably, about 15 kGy to about 25 kGy.
[0147] In above sterilization processes, the gamma irradiation or e-beam irradiation may be performed at temperature in between -80 °C and 35 °C and the gamma irradiation used from about 1 kGy to about 24 kGy; preferably, about 10 kGy to about 24 kGy (OR) the e-beam irradiation used from about 1 kGy to about 50 kGy; preferably about 10 kGy to about 25 kGy. The time for gamma irradiation is about 1 hour to about 6 hours, preferably about 2 hours to about 4 hours; and e-beam irradiation about 1 minute to about 60 minutes, preferably about 5 minutes to about 45 minutes.
[0148] In another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine, and the schematic description of the process is as shown in Scheme-II:
[0149] y-irradaiation:
[0150] Non-sterile Ensifentrine Black LDPE Triple laminated Al bag '-irradaiation Tri. Al + LDPE + Black LDPE +
[0151] LDPE + Black LDPE + , Sterile Heat-Seal Ensiffentririne Heat-Seal Ensifentrine Heat-Seal LDPE + 1 to 24 kGy Ensifentrine
[0152] e-beam irradaiation:
[0153] Non-sterile Ensifentrine Black LDPE Triple laminated Al bag e-beam irradaiation Triri. Al + LDPE + Black LDPE +
[0154] LDPE + Blacck LDPE + SterileLDPEJ Heat-Seal [Ensifentrine] Heat-Seal Ensifentrine Heat-Seal LDPE + 1 to 50 kGy Ensifentrine
[0155] Ensifentrine
[0156]
[0157] Scheme-IIIn another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine, and the schematic description of the process is as shown in Scheme-Ill:
[0158] LDPE + AL Canister:
[0159] y-irradaiation:
[0160] Non-sterile
[0161] Ensifentrine Aluminium canister y-irradaiation
[0162] LDPE + LDPE + Sterile Heat-Seal Ensifentrine Close the Ensifentrine 10 to 15 kGy Ensifentrine
[0163]
[0164] aluminum 2 to 4 h, rt canister with
[0165] chlorobutyl plug
[0166] and tear off aluminum cap
[0167] e-beam irradaiation:
[0168] Non-sterile
[0169] Ensifentrine Aluminium canister e-beam irradaiation
[0170] AL canister + LDPE + LDPE + Sterile
[0171]
[0172] Heat-Se Ensifentrineal Close the Ensifentrine 10 t Ensifentrine m
[0173]
[0174] o 15 kGy alu
[0175]
[0176]
[0177] inum 5 to 20 min, rt
[0178] canister with
[0179] chlorobutyl plug
[0180] and tear off aluminum cap
[0181] Scheme-Ill
[0182] In another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine, and the schematic description of the process is as shown in Scheme-IV :LDPE + Black LDPE + HDPE Drum
[0183] y-irradaiatlon:
[0184] Non-sterile Ensifentrine Black LDPE HDPE Drum y-irradaiation HDPE Drum + LDPE + Black LDPE +
[0185] LDPE Black LDPE + Sterile Ensifentrine + Heat-Seal Ensifentrine Heat-Seal LDPE + 10 to 15 kGy Ensifentrine Ensifentrine 2 to 4 h, rt e-beam irradaiation:
[0186] Non-sterile Ensifentrine Black LDPE HDPE Drum e beam-irradaiation HDPE Drum + LDPE + Black LDPE +
[0187] LDPE Black LDPE + Sterile Ensifentrine + Heat-Seal Ensifentrine Heat-Seal LDPE + 10 to 15 kGy Ensifentrine
[0188]
[0189] Ensifentrine 5 to 10 mins Scheme-IV
[0190] In another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine, and the schematic description of the process is as shown in Scheme-V :
[0191] Triple Laminated Aluminium Bae + HDPE Drum:
[0192] y-irradaiation:
[0193] Non-sterile
[0194] Ensifentrine HDPE Drum Y-irradaiation
[0195] HDPE Drum Triple laminated Sterile + Tri. Al + alumium bag 10 to 15 kGy Ensifentrine Ensifentrine 2 to 4 h, rt
[0196]
[0197] e-beam irradaiation:
[0198] Non-sterile
[0199] Ensifentrine HDPE Drum e beam-irradaiation
[0200] HDPE Drum Triple laminated + Tri. Al + Sterile alumium bag Ensifentrine 10 to 15 kGy Ensifentrine
[0201]
[0202] 5 to 10 mins, rt Scheme-V
[0203] In another embodiment of the present invention provides a process for the preparation of sterile Ensifentrine, and the schematic description of the process is as shown in Scheme- VI:AL Canister + LDPE
[0204] y-irradaiation:
[0205] Non-sterile
[0206] Ensifentrine LDPE Bag Y-irradaiation
[0207] Al. canister
[0208]
[0209] Aluminium LDPE +
[0210] +
[0211]
[0212] Sterile
[0213]
[0214] canister Close the Al. canister +
[0215] Ensifentrine aluminum Ensifentrine 10 to 15 kGy Ensifentrine
[0216]
[0217] 2 to 4 h, rt canister with
[0218] chlorobutyl plug
[0219] and tear off aluminum cap
[0220] e-beam irradaiation:
[0221] Non-sterile
[0222] Ensifentrine LDPE Bag
[0223] e beam -irradaiation LDPE + Al. canister + Sterile 10 to 15 kGy Ensifentrine
[0224]
[0225] Ensifentrine 5 to 10 mins, rt canister with
[0226] chlorobutyl plug
[0227] and tear off aluminum cap
[0228] Scheme- VI
[0229] The Ensifentrine particles comprise Ensifentrine (i.e., Ensifentrine free base) or a pharmaceutically acceptable salt thereof. Typically, the Ensifentrine particles comprise Ensifentrine free base. The Ensifentrine particles typically comprise at least 90.0 wt % of Ensifentrine or a pharmaceutically acceptable salt thereof, preferably at least 95.0 wt %. The Ensifentrine particles may consist essentially of Ensifentrine or a pharmaceutically acceptable salt thereof, or may consist of Ensifentrine or a pharmaceutically acceptable salt thereof. For instance, the Ensifentrine particles may consist of Ensifentrine free base.
[0230] The sterile Ensifentrine particles in the sterile liquid pharmaceutical composition may be suspended in the sterile liquid vehicle. The sterile liquid pharmaceutical composition accordingly typically comprises a suspension of the Ensifentrine particles. It may also be the case that some or all of the Ensifentrine particles in the sterile liquid pharmaceutical composition have settled to the bottom of a receptacle containing the sterile liquid pharmaceutical composition, for instance after storagefor a period of time. The Ensifentrine particles may be re-suspended in any suitable way, for instance by agitation of the sterile liquid pharmaceutical composition.
[0231] The Ensifentrine particles may be produced by any pharmaceutically acceptable size reduction process or particle size-controlled production process. For instance, the particles may be produced by spray-drying a solution of Ensifentrine, by controlled crystallisation, or by size reduction of a solid form of Ensifentrine, for example by air jet milling, mechanical micronisation or media milling.
[0232] The process further comprises combining the sterile Ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. Combining the sterile Ensifentrine particles with a sterile liquid vehicle typically comprises mixing the sterile Ensifentrine particles with a sterile liquid vehicle.
[0233] However, Ensifentrine particles were highly resistant to sterilisation by gamma irradiation or e-beam irradiation, with no significant changes in purity or assay. The sterilised Ensifentrine particles obtained by gamma irradiation or e-beam irradiation can be combined with the suspension vehicle and processing to obtain a sterile suspension formulation comprising Ensifentrine.
[0234] Test for sterilization:
[0235] Sterility test conducted as per pharmacopeial methods (USP <71>, EP 2.6.1) and Bioburden test which measures microbial load before sterilization and after sterilization, it should be zero or within sterile limits.
[0236] Advantages:
[0237] a) Gamma irradiation or e-beam irradiation are having better penetrating capacity that allows the products in the final packaging to be sterilised when compared to heating Ensifentrine particles at a temperature of from 100° C. to 220° C. for sterilization.b) Gamma irradiation or e-beam irradiation does not significantly increase the temperature of the products and therefore can be used to sterilize safely even the heat- sensitive materials as well as materials in frozen condition.
[0238] c) Gamma irradiation or e-beam irradiation sterilization offers several advantages over dry heat sterilization, including its ability to sterilize at lower temperatures, avoid damage to packaging seals, and sterilize a wider range of materials. d) Gamma irradiation or e-beam irradiation is faster and more cost-effective, while also being a safer and environmentally friendly process.
[0239] e) Aluminium doesn't break up into harmful microparticles like plastic.
[0240] f) Aluminium canisters are maintaining cooling properly during the process of gamma irradiation or e-beam irradiation.
[0241] g) Controlled all degradation impurities.
[0242] EXPERIMENTAL PORTION:
[0243] The details of the invention are given in the examples provided below, which are given to illustrate the invention only and therefore should not be construed to limit the scope of the invention.
[0244] PROCEDURES FOR GAMMA IRRADIATION:
[0245] Example 1: Load the Ensifentrine non-sterile (10 grams) sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Place the LDPE bag into a secondary black LDPE bag and remove the air and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Place the above bag into triple-laminated aluminium bag and close the bag with heat seal or twist tie and covering the bag with LDPE cover without air under nitrogen or without nitrogen at room temperature. Place the triple-laminated aluminium bag into the HDPE drum at room temperature. Load the dry ice into HDPE drum and hold the sample for about 1 hour to about 24 hours under dry ice (if room temperature, then holding time is not required). Place the HDPE drum into a thermocol box along with dry ice (if room temperature, then dry ice is not required). Place the thermocol box into aluminium tote box. Expose the aluminium tote box along with sample togamma energy, with a range of gamma energy from about 21 kGy to about 22 kGy for about 2 hours to about 4 hours.
[0246] Example 2: Load the Ensifentrine non-sterile sample (10 grams) in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Place the LDPE bag into a secondary black LDPE bag and remove the air and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Cover the secondary LDPE bag with LDPE cover without air at room temperature. Place the bag into the HDPE drum under nitrogen or without nitrogen at room temperature. Load the dry ice into HDPE drum (if room temperature, then not required) and hold the sample for about 1 hour to about 30 hours under dry ice (if room temperature, then holding time is not required). Place the HDPE drum into a thermocol box along with dry ice (if room temperature, then dry ice is not required). Place the thermocol box into aluminium tote box. Expose the aluminium tote box along with sample to gamma energy, with a range of gamma energy from about 21 kGy to about 22 kGy for about 2 hours to about 4 hours.
[0247] Example 3: Load the Ensifentrine non-sterile sample (10 grams) in LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Place the LDPE bag into aluminium canister under nitrogen or without nitrogen at room temperature. Close the aluminium canister with chlorobutyl plug and tear off aluminium caps under nitrogen or without nitrogen at room temperature. Seal the aluminium canister using a crimper under nitrogen at room temperature. Cover the aluminium canister with LDPE cover, remove the air, seal or twist and tie under nitrogen; Place the canister and load dry ice into the thermocol box (if room temperature, then dry ice is not required) and seal the box with cello tape and hold the box under dry ice for 0 to 24 hours (if room temperature, then holding time is not required). Place the thermocol box into an aluminium tote box along with dry ice (if room temperature then dry ice is not required). Expose the aluminium tote box and sample to gamma energy,with a range of gamma energy from about 21 kGy to about 22 kGy for about 2 hours to about 4 hours.
[0248] Example 4: Load the Ensifentrine non-sterile sample (10 grams) in aluminium canister at room temperature; Close the aluminium canister with chlorobutyl plug and tear off aluminium caps under nitrogen or without nitrogen at room temperature. Seal the aluminium canister using a crimper under nitrogen at room temperature; Cover the aluminium canister with LDPE cover, remove the air and seal or twist and tie under nitrogen. Place the canister and load dry ice into the thermocol box (if room temperature, dry ice is not required) and seal the box with cello tape and hold the box under dry ice for 0 to 24 hours (if room temperature, then holding time is not required). Place the thermocol box into an aluminium tote box along with dry ice (if room temperature, dry ice is not required). Expose the aluminium tote box along with sample to gamma energy, with a range of gamma energy from about 21 kGy to about 22 kGy for about 2 hours to about 4 hours.
[0249] Example 5: Load he Ensifentrine non-sterile sample (10 grams) in triple laminated aluminium bag at room temperature. Close the bag using heat seal or twist and tie under nitrogen or without nitrogen at room temperature. Place the bag into HDPE container. Place the HDPE container into thermocol box and load the dry ice into thermocol box (if room temperature, dry ice is not required) and seal the box with cello tape and hold the box for 0 to 24 hours under dry ice (if room temperature, holding time is not required). Place the thermocol box into the aluminium tote box along with dry ice (if room temperature, dry ice is not required). Expose the aluminium tote box and the sample to gamma energy, with a range of gamma energy from about 21 kGy to about 22 kGy for about 2 hours to about 4 hours.
[0250] PROCEDURES FOR E-BEAM IRRADIATION:
[0251] Example 6: Load the Ensifentrine non-sterile (10 grams) sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Place the LDPE bag into a secondary black LDPE bag and remove the air and seal the bag with heat sealor twist tie under nitrogen or without nitrogen at room temperature. Place the above bag into triple-laminated aluminium bag and close the bag with heat seal or twist tie and covering the bag with LDPE cover without air under nitrogen or without nitrogen at room temperature. Place the triple-laminated aluminium bag into the HDPE drum at room temperature. Load the dry ice into HDPE drum and hold the sample for about 1 hour to about 24 hours under dry ice (if room temperature, then holding time is not required). Place the HDPE drum into a thermocol box along with dry ice (if room temperature, then dry ice is not required). Place the thermocol box into aluminium tote box. Expose the aluminium tote box along with sample to e-beam energy, with a range of e-beam energy from about 20 to about 23 kGy for about 5 minutes to about 20 minutes.
[0252] Example 7: Load the Ensifentrine non- sterile sample (10 grams) in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Place the LDPE bag into a secondary LDPE bag and remove the air and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Cover the secondary LDPE bag with LDPE cover without air at room temperature. Place the bag into the HDPE drum under nitrogen or without nitrogen at room temperature. Load the dry ice into HDPE drum (if room temperature, then not required) and hold the sample for about 1 hour to about 30 hours under dry ice (if room temperature, then holding time is not required). Place the HDPE drum into a thermocol box along with dry ice (if room temperature, then dry ice is not required). Place the thermocol box into aluminium tote box. Expose the aluminium tote box along with sample to e-beam energy, with a range of e-beam energy from about 20 kGy to about 23 kGy for about 5 minutes to about 20 minutes.
[0253] Example 8: Load the Ensifentrine non-sterile sample (10 grams) in LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie under nitrogen or without nitrogen at room temperature. Place the LDPE bag into aluminium canister under nitrogen or without nitrogen at room temperature. Close the aluminium canister with chlorobutyl plug and tear off aluminium caps undernitrogen or without nitrogen at room temperature. Seal the aluminium canister using a crimper under nitrogen at room temperature. Cover the aluminium canister with LDPE cover, remove the air, seal or twist and tie under nitrogen; Place the canister and load dry ice into the thermocol box (if room temperature, then dry ice is not required) and seal the box with cello tape and hold the box under dry ice for 0 to 24 hours (if room temperature, then holding time is not required). Place the thermocol box into an aluminium tote box along with dry ice (if room temperature then dry ice is not required). Expose the aluminium tote box and sample to e-beam energy, with a range of e-beam energy from about 20 to about 23 kGy for about 5 minutes to about 20 minutes.
[0254] Example 9: Load the Ensifentrine non-sterile sample (10 grams) in aluminium canister at room temperature; Close the aluminium canister with chlorobutyl plug and tear off aluminium caps under nitrogen or without nitrogen at room temperature. Seal the aluminium canister using a crimper under nitrogen at room temperature; Cover the aluminium canister with LDPE cover, remove the air and seal or twist and tie under nitrogen. Place the canister and load dry ice into the thermocol box (if room temperature, dry ice is not required) and seal the box with cello tape and hold the box under dry ice for 0 to 24 hours (if room temperature, then holding time is not required). Place the thermocol box into an aluminium tote box along with dry ice (if room temperature, dry ice is not required). Expose the aluminium tote box along with sample to e-beam energy, with a range of e-beam energy from about 20 kGy to about 23 kGy for about 5 minutes to about 20 minutes.
[0255] Example 10: Load he Ensifentrine non-sterile sample (10 grams) in triple laminated aluminium bag at room temperature. Close the bag using heat seal or twist and tie under nitrogen or without nitrogen at room temperature. Place the bag into HDPE container. Place the HDPE container into thermocol box and load the dry ice into thermocol box (if room temperature, dry ice is not required) and seal the box with cello tape and hold the box for 0 to 24 hours under dry ice (if room temperature, holding time is not required). Place the thermocol box into the aluminium tote box along with dry ice (if room temperature, dry ice is not required).Expose the aluminium tote box and the sample to e-beam energy, with a range of e-beam energy from about 20 kGy to about 23 kGy for about 5 minutes to about 20 minutes.
Claims
We claim:
1. A process for the preparation of sterile Ensifentrine of Formula-I,which comprises:i. placing the Ensifentrine non- sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature;ii. placing the LDPE bag into a secondary LDPE bag and remove the air and seal the bag with heat seal or twist tie at room temperature;iii. placing the above bag into triple-laminated aluminium bag and close the bag with heat seal or twist tie and covering the bag with LDPE cover without air at room temperature;iv. placing the triple-laminated aluminium bag into the HDPE drum at room temperature;v. loading the dry ice into HDPE drum and hold the sample for about 1 hour to about 30 hours under dry ice;vi. placing the HDPE drum into a thermocol box along with dry ice;vii. placing the thermocol box into aluminium tote box; andviii. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy;ORexposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
2. A process for the preparation of sterile Ensifentrine of Formula-I,MeOwhich comprises:i. placing the Ensifentrine non- sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature;ii. placing the LDPE bag into a secondary LDPE bag and remove the air and seal the bag with heat seal or twist tie at room temperature;iii. covering the secondary LDPE bag with LDPE cover without air at room temperature;iv. placing the bag into the HDPE drum at room temperature;v. loading the dry ice into HDPE drum and hold the sample for about 1 hour to about 30 hours under dry ice;vi. placing the HDPE drum into a thermocol box along with dry ice;vii. placing the thermocol box into aluminium tote box; andviii. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy;ORexposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
3. A process for the preparation of sterile Ensifentrine of Formula-I,MeOwhich comprises:i. placing the Ensifentrine non- sterile sample in food grade LDPE bag and remove the air from the bag and seal the bag with heat seal or twist tie at room temperature;ii. placing the LDPE bag into aluminium canister at room temperature; iii. closing the aluminium canister with chlorobutyl plug and tear off aluminium caps at room temperature;iv. sealing the aluminium canister using a crimper at room temperature; v. covering the aluminium canister with LDPE cover, remove the air, seal or twist and tie;vi. placing the canister and load dry ice into the thermocol box and seal the box with cello tape and hold the box under dry ice for about 1 hour to about 30 hours;vii. placing the thermocol box into an aluminium tote box along with dry ice;andviii. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy;ORexposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
4. A process for the preparation of sterile Ensifentrine of Formula-I,MeOwhich comprises:i. placing the Ensifentrine non-sterile sample in aluminium canister at room temperature;ii. closing the aluminium canister with chlorobutyl plug and tear off aluminium caps at room temperature;iii. sealing the aluminium canister using a crimper at room temperature; iv. covering the aluminium canister with an LDPE cover, remove the air and seal or twist and tie;v. placing the canister and load dry ice into the thermocol box and seal the box with cello tape and hold the box under dry ice for about 1 hour to about 30 hours;vi. placing the thermocol box into an aluminium tote box along with dry ice;andvii. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 hour to about 24 kGy;ORexposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
5. A process for the preparation of sterile Ensifentrine of Formula-I,MeOwhich comprises:i. placing the Ensifentrine non-sterile sample in triple laminated aluminium bag at room temperature;ii. closing the bag using heat seal or twist and tie at room temperature; iii. placing the bag into HDPE container;iv. placing the HDPE container into thermocol box and loading the dry ice into thermocol box and seal the box with cello tape and hold the box for about 1 hour to about 30 hours under dry ice.v. placing the thermocol box into the aluminium tote box along with dry ice;andvi. exposing the aluminium tote box along with sample to gamma energy, with an energy range from about 1 kGy to about 24 kGy;ORexposing the aluminium tote box along with sample to e-beam energy, with an energy range from about 1 kGy to about 50 kGy.
6. The process as claimed in claims 1 to 5, wherein the Ensifentrine has a temperature ranging from about -80 °C to about 35 °C.
7. The process as claimed in claims 1 to 5, wherein the process comprises exposure of Ensifentrine non-sterile sample to gamma energy range from about 15 kGy to about 24 kGy for a time period of about 1 hour to about 6 hours.
8. The process as claimed in claims 1 to 5, wherein the process comprises exposure of Ensifentrine non- sterile sample to e-beam energy range from about 15 kGy to about 25 kGy for a time period of about 1 minutes to about 60 minutes.
9. A process according to any one of the preceding claims, wherein the Ensifentrine has a particle size distribution with a Dv50 of from about 0.1 pm to about 10.0 pm.
10. A process according to any one of the preceding claims, wherein the Ensifentrine has a particle size distribution with a Dv50 of from about 0.1 pm to about 5.0 pm.
